UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA)

Annals of oncology, 2018-10, Vol.29, p.viii319-viii320

2018

Volltextzugriff (PDF)

Updated results of GETUG-12, a phase III trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up

Annals of oncology, 2018-10, Vol.29, p.viii271-viii271

2018

Volltextzugriff (PDF)

Efficacy and safety of axitinib in metastatic papillary renal carcinoma (mPRC): Results of a GETUG multicenter phase II trial (Axipap)

Annals of oncology, 2018-10, Vol.29, p.viii307-viii307

2018

Volltextzugriff (PDF)

2591 Surgical resection of brain metastasis from renal cancer: Is it worth it? The experience of a French Cancer Center

European journal of cancer (1990), 2015-09, Vol.51, p.S508-S509

2015

Volltextzugriff (PDF)

RANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results

Annals of oncology, 2018-10, Vol.29, p.viii304-viii305

2018

Volltextzugriff (PDF)

2541 Updated results of the FLAC European database of metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with life extending therapies in post-docetaxel (D) setting

European journal of cancer (1990), 2015-09, Vol.51, p.S489-S489

2015

Volltextzugriff (PDF)

2538 Response to cabazitaxel in patients with metastatic castrationresistant prostate cancer (mCRPC) poorly responding to docetaxel

European journal of cancer (1990), 2015-09, Vol.51, p.S488-S488

2015

Volltextzugriff (PDF)

Randomized phase III trial of dose-dense MVAC or GC as perioperative chemotherapy for muscle-invasive urothelial bladder cancer (MIUBC): Preliminary results of the GETUG/AFU V05 VESPER trial on toxicity and pathological responses

European urology open science (Online), 2020-07, Vol.19, p.e108-e109

2020

Volltextzugriff (PDF)

31LBA MOST – My Own Specific Therapy – A multicenter, randomized, open-label, phase II trial evaluating the clinical benefit of a maintenance treatment targeting tumor molecular alterations in patients with advanced solid tumors: preliminary results from the everolimus and sorafenib cohorts

European journal of cancer (1990), 2015-09, Vol.51, p.S725-S726

2015

Volltextzugriff (PDF)

Venous thromboembolic events stratified by number of risk factors in patients with metastatic germ cell tumours undergoing first-line chemotherapy

European urology open science (Online), 2020-07, Vol.19, p.e398-e399

2020

Volltextzugriff (PDF)

Prise en charge des tératomes testiculaires : mise au point par le Comité de cancérologie de l’Association française d’urologie groupe organes génitaux externes (CCAFU-OGE)

Progrès en urologie (Paris), 2014-12, Vol.24 (16), p.1050-1053

2014

Volltextzugriff (PDF)

1814P First real-life data on [177Lu]Lu-PSMA-617: Descriptive analysis on the largest metastatic castration-resistant prostate cancer (mCRPC) cohort treated in early access in France

Annals of oncology, 2023-10, Vol.34, p.S983-S983

2023

Volltextzugriff (PDF)

Chemotherapy feasibility in older patients with metastatic bladder cancer: The Multicenter prospective cohort study Agevim

Journal of geriatric oncology, 2014-10, Vol.5, p.S16-S17

2014

Volltextzugriff (PDF)

TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes

Annals of oncology, 2024-04, Vol.35 (4), p.392-401

2024

Volltextzugriff (PDF)

Récidives tardives des tumeurs germinales du testicule

Progrès en urologie (Paris), 2010-06, Vol.20 (6), p.416-424

2010

Volltextzugriff (PDF)

1906P Metastasized non-clear cell renal cell carcinoma: Which entities are dangerous? Results learned from reference pathology of the SuniForecast study

Annals of oncology, 2023-10, Vol.34, p.S1026-S1026

2023

Volltextzugriff (PDF)

2379P AVENANCE: Subgroup analysis of patients (pts) with advanced urothelial carcinoma (aUC) with histological variants from a real-world (RW) study of avelumab first-line maintenance (1LM)

Annals of oncology, 2023-10, Vol.34, p.S1211-S1212

2023

Volltextzugriff (PDF)

736P Residual masses after salvage chemotherapy in men with metastatic seminoma: The Semi-ResMass multicenter retrospective study

Annals of oncology, 2023-10, Vol.34, p.S505-S505

2023

Volltextzugriff (PDF)

1062P Anti-PD1 efficacy in European patients with advanced MSI-H/MMRd non-colorectal cancers

Annals of oncology, 2023-10, Vol.34, p.S642-S642

2023

Volltextzugriff (PDF)

Facteurs de récidive après curage rétro-péritonéal pour tumeur germinale : étude rétrospective multicentrique

Progrès en urologie (Paris), 2014-11, Vol.24 (13), p.865-865

2014

Volltextzugriff (PDF)

652O Dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for patients with muscle-invasive bladder cancer (MIBC): Results of the GETUG/AFU VESPER V05 phase III trial

Annals of oncology, 2021-09, Vol.32, p.S678-S678

2021

Volltextzugriff (PDF)

1364MO Preliminary phase II results of the CYPIDES study of ODM-208 in metastatic castration-resistant prostate (mCRPC) cancer patients

Annals of oncology, 2022-09, Vol.33, p.S1165

2022

Volltextzugriff (PDF)

Rôle de la chimiothérapie dans la prise en charge du cancer de la vessie

Progrès en urologie (Paris), 2011-06, Vol.21 (6), p.369-382

2011

Volltextzugriff (PDF)

2364MO Durvalumab (D) +/- tremelimumab (T) in combination with dose-dense MVAC (ddMVAC) as neoadjuvant treatment in patients with muscle-invasive bladder carcinoma (MIBC): Results of NEMIO, a randomized phase I-II trial

Annals of oncology, 2023-10, Vol.34, p.S1202-S1202

2023

Volltextzugriff (PDF)

LBA13 Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)

Annals of oncology, 2023-10, Vol.34, p.S1324-S1325

2023

Volltextzugriff (PDF)

1 – 25 von 528

Suche als RSS-Feed

Aktive Filter

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(428)
Mit Volltextzugriff
(420)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(35)
Male
(34)
Physics
(34)
Life Sciences
(29)
Animals
(23)
Physics Archives
(22)
Science & Technology
(22)
Sciences Biologiques Et Medicales
(22)
Sciences Medicales
(22)
Female
(20)
Tumeurs
(17)
Technology
(15)
Chemotherapy
(14)
Hematology, Oncology And Palliative Medicine
(14)
Biological And Medical Sciences
(13)
Materials Science
(13)
Chimiothérapie
(12)
Radiotherapy
(12)
Materials Science, Multidisciplinary
(11)
Physical Sciences
(11)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA)

Updated results of GETUG-12, a phase III trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up

Efficacy and safety of axitinib in metastatic papillary renal carcinoma (mPRC): Results of a GETUG multicenter phase II trial (Axipap)

2591 Surgical resection of brain metastasis from renal cancer: Is it worth it? The experience of a French Cancer Center

RANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results

2541 Updated results of the FLAC European database of metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with life extending therapies in post-docetaxel (D) setting

2538 Response to cabazitaxel in patients with metastatic castrationresistant prostate cancer (mCRPC) poorly responding to docetaxel

Randomized phase III trial of dose-dense MVAC or GC as perioperative chemotherapy for muscle-invasive urothelial bladder cancer (MIUBC): Preliminary results of the GETUG/AFU V05 VESPER trial on toxicity and pathological responses

31LBA MOST – My Own Specific Therapy – A multicenter, randomized, open-label, phase II trial evaluating the clinical benefit of a maintenance treatment targeting tumor molecular alterations in patients with advanced solid tumors: preliminary results from the everolimus and sorafenib cohorts

Venous thromboembolic events stratified by number of risk factors in patients with metastatic germ cell tumours undergoing first-line chemotherapy

Prise en charge des tératomes testiculaires : mise au point par le Comité de cancérologie de l’Association française d’urologie groupe organes génitaux externes (CCAFU-OGE)

1814P First real-life data on [177Lu]Lu-PSMA-617: Descriptive analysis on the largest metastatic castration-resistant prostate cancer (mCRPC) cohort treated in early access in France

Chemotherapy feasibility in older patients with metastatic bladder cancer: The Multicenter prospective cohort study Agevim

TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes

Récidives tardives des tumeurs germinales du testicule

1906P Metastasized non-clear cell renal cell carcinoma: Which entities are dangerous? Results learned from reference pathology of the SuniForecast study

2379P AVENANCE: Subgroup analysis of patients (pts) with advanced urothelial carcinoma (aUC) with histological variants from a real-world (RW) study of avelumab first-line maintenance (1LM)

736P Residual masses after salvage chemotherapy in men with metastatic seminoma: The Semi-ResMass multicenter retrospective study

1062P Anti-PD1 efficacy in European patients with advanced MSI-H/MMRd non-colorectal cancers

Facteurs de récidive après curage rétro-péritonéal pour tumeur germinale : étude rétrospective multicentrique

652O Dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for patients with muscle-invasive bladder cancer (MIBC): Results of the GETUG/AFU VESPER V05 phase III trial

1364MO Preliminary phase II results of the CYPIDES study of ODM-208 in metastatic castration-resistant prostate (mCRPC) cancer patients

Rôle de la chimiothérapie dans la prise en charge du cancer de la vessie

2364MO Durvalumab (D) +/- tremelimumab (T) in combination with dose-dense MVAC (ddMVAC) as neoadjuvant treatment in patients with muscle-invasive bladder carcinoma (MIBC): Results of NEMIO, a randomized phase I-II trial

LBA13 Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)

Aktive Filter

Suchergebnisse filtern